{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T13:53:43Z","timestamp":1753883623347,"version":"3.41.2"},"reference-count":10,"publisher":"The Endocrine Society","issue":"1","license":[{"start":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T00:00:00Z","timestamp":1670025600000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Immune checkpoint inhibitors (ICIs) are frequently used as treatment for many malignancies. Immune-related adverse events (irAEs) due to use of ICIs are common. Thyroid involvement is the most common endocrine irAE. Here, we present an unusual case of Graves' disease potentially cured due to destructive thyroiditis caused by inflammation due to ICIs. Thyroid irAEs are more common with programmed cell death protein-1 (PD-1) inhibitor or programmed cell death-ligand 1 (PD-L1) inhibitors than cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors. Baseline and serial monitoring of thyroid function tests is recommended.<\/jats:p>","DOI":"10.1210\/jcemcr\/luac024","type":"journal-article","created":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T11:03:16Z","timestamp":1670065396000},"source":"Crossref","is-referenced-by-count":1,"title":["Hypothyroidism After Use of Immune Checkpoint Inhibitor Therapy in Patient With Graves' Disease: Cure?"],"prefix":"10.1210","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1342-7153","authenticated-orcid":false,"given":"Rajeev","family":"Sharma","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Roswell Park Comprehensive Cancer Center & Jacobs School of Medicine and Biomedical Sciences, University at Buffalo , New York, NY 14203 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2022,12,3]]},"reference":[{"issue":"1","key":"2023100215455641100_luac024-B1","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat Commun"},{"issue":"8","key":"2023100215455641100_luac024-B2","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"issue":"4","key":"2023100215455641100_luac024-B3","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoint skin cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"2023100215455641100_luac024-B4","doi-asserted-by":"crossref","first-page":"559","DOI":"10.4103\/ijmr.IJMR_313_19","article-title":"The side effects of immune checkpoint inhibitor therapy on the endocrine system","volume":"154","author":"Goyal","year":"2021","journal-title":"Indian J Med Res"},{"issue":"6","key":"2023100215455641100_luac024-B5","doi-asserted-by":"crossref","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"Suppl 3","key":"2023100215455641100_luac024-B6","first-page":"A909","article-title":"856 Preliminary review of diabetes mellitus incidence in patients treated with immune checkpoint inhibitors (ICI) therapy\u2014Roswell Park Comprehensive Cancer Center (RPCCC) experience","volume":"8","author":"Zhang","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"11","key":"2023100215455641100_luac024-B7","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1210\/jc.2016-2300","article-title":"Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab","volume":"101","author":"de Filette","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2023100215455641100_luac024-B8","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"issue":"8","key":"2023100215455641100_luac024-B9","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.3390\/cancers13081944","article-title":"Graves\u2019 disease during immune checkpoint inhibitor therapy (a case series and literature review)","volume":"13","author":"Peiffert","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"4","key":"2023100215455641100_luac024-B10","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1159\/000501824","article-title":"Graves\u2019 disease induced by immune checkpoint inhibitors: a case report and review of the literature","volume":"8","author":"Brancatella","year":"2019","journal-title":"Eur Thyroid J"}],"container-title":["JCEM Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcemcr\/advance-article-pdf\/doi\/10.1210\/jcemcr\/luac024\/47658179\/luac024.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/1\/1\/luac024\/51825142\/luac024.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/1\/1\/luac024\/51825142\/luac024.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T15:46:28Z","timestamp":1696261588000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcemcr\/article\/doi\/10.1210\/jcemcr\/luac024\/6868532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,29]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,11,29]]}},"URL":"https:\/\/doi.org\/10.1210\/jcemcr\/luac024","relation":{},"ISSN":["2755-1520"],"issn-type":[{"type":"electronic","value":"2755-1520"}],"subject":[],"published-other":{"date-parts":[[2023,1,1]]},"published":{"date-parts":[[2022,11,29]]},"article-number":"luac024"}}